Nacimbio, the pharmaceutical holding of the Rostec State Corporation, concluded eight new contracts with the Ministry of Health of the Russian Federation for the supply of four units (INN) of blood plasma products: blood-coagulation factors IX, VIII, including with von Willebrand factor and anti-inhibitor coagulant complex.
Under the terms of the contracts, Nacimbio will supply to the constituent entities of the Russian Federation over 173 million international units (IU) of blood coagulation factors and about 20 million units (EA) of anti-inhibitor coagulant complexes before September 1.
Except for Moscow and the Moscow Region, the largest volume of ordered products will be directed to the Krasnodar Territory, St. Petersburg, the Republic of Dagestan, Omsk Region, and Sverdlovsk Region; in total, about 76 million units will be supplied to the regions.
For the purposes of vaccines supply, the Holding develops a high-technology cold chain in Russia, which consolidates its own fleet of specialized vehicles, the system of warehouse logistics, storage and transport standards. For the first time this year, new technological solutions are used to minimize the violability of temperature conditions. In particular, latest-generation thermal containers maintaining the required temperature conditions are used continuously for a week. Nacimbio also introduces a comprehensive system for remote and continuous monitoring of the cargoes location.
The value of signed state contracts exceeded 3.4 billion rubles. Earlier this year, Nacimbio fulfilled its obligations to supply similar INN drug products in full, with a prior shipment of more than 223 million IU “factors” and about 20 million EA drug products of anti-inhibitor coagulant complex to the Agency.
The first Additional Pharmacological Support Program (DLO) for the medication support for hemophiliacs in Russia began in 2005, the second one – “Seven Nosologies Program” – is in effect since 2008. Currently, according to the standard of the disease treatment, patients receive replacement therapy with coagulation factor concentrates, which prevent bleeding and hemorrhage.
In March 2018, the Government of the Russian Federation re-established Nacimbio, JSC, as the sole supplier of medicinal products derived from the blood plasma of humans and animals, which the federal authorities and their subordinated institutions procure in 2018 and for 2019. From 2016 to 2017, as part of its sole-supplier function, Nacimbio supplied over 800 million IU blood plasma products for the state needs as and when appropriate and required.